Pharma News

Seagen Canada announced the commercial availability of PADCEV® (enfortumab vedotin) for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) wh...

The UCL study will evaluate the safety and effectiveness of MTL-CEBPA in combination with second line standard of care sorafenib versus the use of sorafenib in isolation ...

The FDA has approved AbbVie’s Skyrizi (risankizumab-rzaa) for treating adults with psoriatic arthritis, an inflammatory disease that afflicts an estimated 30 percent of psoriasis sufferers. ...

The treatment must be given via intravenous infusion over three consecutive days, generally at a hospital or clinic.

Belgian pharmaceuticals company UCB has been given permission to market its treatment for psoriasis, Bimzelx (bimekizumab) in Japan, the company announced today. ...

Two health care companies – one based in Massachusetts called Biogen and its Japanese partner Eisai Co. – recently were granted “fast track” approval by the U.S. Food and Drug Administratio...

Elon Musk’s brain-machine interface company Neuralink has a new job posting for a clinical trial director, a position that could help the company move towards its stated goal of testing its brain...

Nearly 3,000 devices receive approval from the FDA each year, according to Pathogenomix Chairman Chris Risley, but only 75 receive a Breakthrough Device Designation. ...

The United Nations-backed Medicines Patent Pool (MPP) has secured agreements with 27 generics makers in Asia and Africa to supply Merck’s COVID-19 oral antiviral, molnupiravir, in 105 low- and mi...

In a study published in the latest issue of the journal Materials Today Advances, a team of researchers explored the utilities of graphene (GO) and its derivatives in combating the severe acute res...

Patrick Soon-Shiong, South African-born head of biotech firms NantWorks and ImmunityBio, has launched a new manufacturing facility in South Africa with the goal of producing 1 billion COVID-19 vacc...

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered into a drug discovery collaboration with Eli Lilly and Company i...